Organizations commit to expanding the impact of genomics and
advanced health intelligence among diverse populations to address
disparities in personalized health
NorthShore University HealthSystem (NorthShore) and Sema4, a
patient-centered health intelligence company, today announced the
availability of a system-wide data-driven genomics program that
utilizes predictive analytics to help clinicians and patients
prevent, detect, and treat diseases at an early stage, when they
are most treatable. As part of the program, NorthShore clinicians
and patients will have access to Sema4’s industry-leading,
information-rich genomic solutions for hereditary cancer,
cardiovascular diseases, pharmacogenomics, and rare diseases.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210419005296/en/
“Unlocking the power of genomics in patient care requires us to
make information available in a way that clinicians and patients
can easily act upon over time,” said Peter Hulick, MD, director of
the Mark R. Neaman Center for Personalized Medicine at NorthShore.
“The partnership between NorthShore and Sema4 will allow us to get
even better at delivering on the promise of genomic insights to
prevent, detect, and manage diseases through one of the largest and
most comprehensive personalized medicine programs in the
country.”
Advanced Clinical Offerings
By combining clinical information with genomic analysis, Sema4’s
technology platform structures and evaluates data sets to draw
insights on how genetic variants will impact patients’ chances of
developing disease and to determine the most appropriate treatment
options, helping their doctors administer more personalized,
holistic care plans. NorthShore will have the opportunity to
benefit from disease network models developed by Sema4. For
example, disease models for cancers will provide more comprehensive
views of cancer patients, their tumor progression, and how best to
diagnose or treat them.
Amidst the pandemic, as evidence reflects people are delaying
preventative care, these more personalized genomic insights are
particularly relevant in helping patients and physicians make
informed decisions about prioritizing care.
“By narrowing the significant gap between available biomedical
data and health and disease information, we are enabling NorthShore
clinicians to make real-time use of the latest insights that allow
for highly informed decisions at the point-of-care and improved
health outcomes,” said Eric Schadt, PhD, Founder and Chief
Executive Officer of Sema4. “NorthShore has done what few health
systems in the country have – brought the potential of genomics
from the research labs to the front lines of care. Through the
implementation of Sema4's innovative health intelligence platform
in a clinical-care setting, we are together advancing industry
standards.”
Improved Patient and Clinician Experiences
In addition to guiding clinicians, the program makes it easier
for NorthShore patients to understand the implications of genomic
findings. Novel digital tools and resources will uncover
personalized insights that shape the care of multiple conditions
throughout the lifetimes of patients. Patients also have an
opportunity to consent to share de-identified data to improve
research programs focused on expanding the understanding of
genomic-guided care.
The strategic alliance between NorthShore and Sema4 will
significantly expand on NorthShore’s existing clinical genomics
offerings, which were already the largest in routine primary care
in the U.S. More than 1,000 physicians and approximately 300,000
NorthShore patients will have access to Sema4’s offerings.
“Precision medicine represents the next major transformation in
health care, allowing us to predict and prevent disease, to
identify the right treatment at the right time, and to empower
patients and clinicians to make better choices about health,” said
J.P. Gallagher, President and Chief Executive Officer of
NorthShore. “This advanced genomics and health intelligence
initiative with Sema4 builds on our long history of pioneering
technology and genomic advancements to improve patient care – and
aligns with our strong commitment to improving the accessibility of
our best-in-class care to address documented disparities in health
care services, disease prevalence, and outcomes.”
Addressing Disparities in Care
Due to NorthShore’s intentional focus on increasing access to
advanced clinical programs, the program is launching in conjunction
with an investment to engage culturally diverse communities. In
addition to understanding and addressing barriers to access,
NorthShore, via a gift from the Swedish Hospital Foundation, will
subsidize genetic testing costs for patients who do not have the
financial resources to pay for testing.
Earlier this month, NorthShore began offering the program to
patients of Swedish Hospital, a State of Illinois Safety Net
Hospital located in a federally designated Medically Underserved
Area and a member of the NorthShore family. Through the program,
the system expects to gain insights about the views of diverse
patient populations towards personalized medicine and barriers to
receiving genetic information and testing.
About NorthShore University
HealthSystem
Headquartered in Evanston, Illinois, NorthShore is a fully
integrated healthcare delivery system that includes six
hospitals—Evanston, Glenbrook, Highland Park, Skokie, Swedish and
Northwest Community. NorthShore consistently ranks as a Top 15
Major Teaching Hospital in the United States, with an established
reputation for exceptional patient care and is a national pioneer
in the implementation of advanced health information technology.
Together, the NorthShore system provides clinical excellence and
community-focused care across Chicagoland. For more information,
please visit NorthShore.org, SwedishCovenant.org and NCH.org.
About Sema4
Sema4 is an AI-driven patient-centered genomic and clinical data
insight platform company founded on the idea that more information,
deeper analysis, and increased engagement will improve the
diagnosis, treatment, and prevention of disease. Sema4 is dedicated
to transforming healthcare by building dynamic models of human
health and defining optimal, individualized health trajectories,
starting in the areas of reproductive health and oncology.
Centrellis™, Sema4’s innovative health intelligence platform, is
enabling Sema4 to generate a more complete understanding of disease
and wellness and to provide science-driven solutions to the most
pressing medical needs. Sema4 believes that patients should be
treated as partners, and that data should be shared for the benefit
of all. For more information, please visit sema4.com and connect
with Sema4 on Twitter, LinkedIn, Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210419005296/en/
NorthShore Media Contact: Colette Urban
curban@northshore.org
Sema4 Media Contact: Radley Moss radley.moss@sema4.com
CM Life Sciences (NASDAQ:CMLF)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
CM Life Sciences (NASDAQ:CMLF)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024